Alvotech Raises $165M via Public Offering to Fund Biosimilar Operations

Key Facts

In a move reflecting the ongoing need for capital in the capital-intensive biotech sector, Alvotech has closed a public offering of its ordinary shares at $3.75 per share. According to reports, the company raised a total of $165 million after underwriters fully exercised their option to purchase additional shares. The proceeds from the issuance of over 26 million shares are designated to fund the company's operations and development within the biosimilar medicines market.

This capital raise follows a broader trend of biotech firms seeking liquidity to sustain long-term research and development cycles. Per market data, institutional demand for biosimilar producers remains resilient, evidenced by the full exercise of the over-allotment option in this deal. While equity offerings often introduce short-term dilution, the successful completion of this $165 million round provides Alvotech with a necessary cash runway to compete with larger peers in the specialized medicine space.